{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:47:48Z","timestamp":1789202868938,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejcancer.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.ejca.2014.07.009","type":"journal-article","created":{"date-parts":[[2014,10,9]],"date-time":"2014-10-09T05:03:24Z","timestamp":1412831004000},"page":"2939-2949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":115,"title":["SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status"],"prefix":"10.1016","volume":"50","author":[{"given":"J.","family":"Maguire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"McMenemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"O\u2019Rourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"McNee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Peedell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Snee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2014.07.009_b0005","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1016\/j.ejca.2014.07.009_b0010","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2014.07.009_b0015","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002140.pub3","article-title":"Concurrent chemoradiotherapy in non-small cell lung cancer","volume":"16","author":"O\u2019Rourke","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"35","key":"10.1016\/j.ejca.2014.07.009_b0020","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1200\/JCO.2008.17.7840","article-title":"Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and US Oncology","volume":"26","author":"Hanna","year":"2008","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2014.07.009_b0025","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2007.14.4824","article-title":"Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023","volume":"26","author":"Kelly","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9687","key":"10.1016\/j.ejca.2014.07.009_b0030","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(09)60737-6","article-title":"Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial","volume":"374","author":"Albain","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2014.07.009_b0035","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.7501","article-title":"A randomised phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617","volume":"31","author":"Bradley","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.07.009_b0040","unstructured":"ICRU (The International Commission on Radiation Units and Measurements) Report 50: Prescribing, recording and reporting Photon Beam Therapy. Landberg T, Chavandra J and Dobbs et al. 1993 ICRU Publications Bethesda."},{"issue":"26","key":"10.1016\/j.ejca.2014.07.009_b0045","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2014.07.009_b0050","unstructured":"SAS Institute Inc Cary, NC."},{"issue":"1","key":"10.1016\/j.ejca.2014.07.009_b0055","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.radonc.2013.07.014","article-title":"Accelerated hypo-fractionated radiotherapy for non small cell lung cancer: results from 4 UK centres","volume":"109","author":"Din","year":"2013","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2014.07.009_b0060","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2006.09.005","article-title":"Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973)","volume":"43","author":"Belderbos","year":"2007","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2014.07.009_b0065","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0167-8140(99)00087-0","article-title":"Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART steering committee","volume":"52","author":"Saunders","year":"1999","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2014.07.009_b0070","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.radonc.2011.06.031","article-title":"Final results of the randomised phase IIICHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC)","volume":"100","author":"Baumann","year":"2011","journal-title":"Radiother Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2014.07.009_b0075","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1200\/JCO.2005.09.108","volume":"23","author":"Belani","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2014.07.009_b0080","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.ijrobp.2010.06.053","article-title":"Induction chemotherapy and continuous hyperfractionated accelerated radiotherapy (chart) for patients with locally advanced inoperable non-small-cell lung cancer: the MRC INCH randomised trial","volume":"81","author":"Hatton","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2014.07.009_b0085","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1200\/JCO.2012.41.6677","article-title":"Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis","volume":"22","author":"Maguen","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2014.07.009_b0090","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(13)70158-X","article-title":"Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients\u2019 data","volume":"14","author":"Mauguen","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2014.07.009_b0095","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.ijrobp.2011.12.032","article-title":"Are the results of RTOG 0617 mysterious?","volume":"82","author":"Cox","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914008090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914008090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T12:48:36Z","timestamp":1598359716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804914008090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":19,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0959804914008090"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2014.07.009","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2014.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}